Betta Pharmaceuticals Co.Ltd(300558)
The prior approval opinions of independent directors on matters related to the 28th meeting of the third board of directors are in accordance with the guiding opinions on the establishment of independent director system in listed companies and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies issued by China Securities Regulatory Commission In accordance with the relevant provisions of laws and regulations such as the Listing Rules of Shenzhen Stock Exchange on the gem and Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as the “company”), the working system of independent directors, in a serious and responsible attitude, and based on the independent, prudent and objective position, we discuss the relevant matters to be considered by the company at the 28th meeting of the third board of directors, After listening to the reports of relevant personnel and reviewing relevant materials, and after careful discussion and review, the following prior approval opinions are issued: I. prior approval opinions on the proposal on investment in Zhejiang shimai Pharmaceutical Co., Ltd. and related party transactions
The company’s foreign investment is conducive to accelerating the company’s layout in the field of antibody drugs and expanding the in-depth exchange of innovative drug technologies, which is in line with the company’s development strategy. The transaction pricing follows the market-oriented principle and does not damage the interests of the company and shareholders, especially small and medium-sized shareholders. We unanimously agreed to submit the matter to the 28th meeting of the third board of directors for deliberation, and the related directors withdrew from voting in accordance with relevant laws, regulations and the articles of association. 2、 Prior approval opinions on the proposal on the transfer of part of the equity and related party transactions of Zhejiang shimai Pharmaceutical Co., Ltd
The related party transaction of the company’s acquisition of part of the equity of Zhejiang shimai Pharmaceutical Co., Ltd. follows the principles of equality, voluntariness, fairness and rationality, and the pricing follows the market-oriented principle. There is no situation that damages the interests of the company and shareholders, especially minority shareholders. We unanimously agreed to submit the matter to the 28th meeting of the third board of directors for deliberation, and the related directors withdrew from voting in accordance with relevant laws, regulations and the articles of association.
(no text below)
[there is no text on this page, which is the signature page of Betta Pharmaceuticals Co.Ltd(300558) independent directors’ prior approval opinions on matters related to the 28th meeting of the third board of directors] independent directors:
Jiangnan Cai Zhao Jun, Wang Wei, Huang Xinqi January 17, 2022
